These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 5465060)
1. [Therapeutic agents for lipid metabolism disorders--with special reference to fatty liver]. Okabe K; Fujisawa K; Takahashi T Nihon Rinsho; 1970 Mar; 28():Suppl:700-3. PubMed ID: 5465060 [No Abstract] [Full Text] [Related]
2. [Therapeutic agents for lipid metabolism disorders--with special reference to arterial diseases]. Murakami M; Sekimoto H; Nagai T; Nakata I; Takekoshi T Nihon Rinsho; 1970 Mar; 28 Suppl():696-9. PubMed ID: 5430846 [No Abstract] [Full Text] [Related]
3. [Changes of plasma lipid levels in patients undergoing long-term hemodialysis--with special reference to the effects of antilipemic drugs and fatty acid emulsion]. Tsuchiya M; Kawamura J Nihon Jinzo Gakkai Shi; 1975 Apr; 17(4):195-207. PubMed ID: 1239595 [No Abstract] [Full Text] [Related]
4. [Efficacy comparison between bicyclol and polyene phosphatidylcholine treatments for the patients with nonalcoholic fatty liver disease]. Su HL; Zhu YX; Gao ZJ; Dong XY; Zhu JY; Lei WR; Zhang Y; Han Y Zhonghua Gan Zang Bing Za Zhi; 2011 Jul; 19(7):552-3. PubMed ID: 22152250 [No Abstract] [Full Text] [Related]
5. [Advisability of using probiotics in the treatment of atherogenic dyslipidemia]. Zvenigorodskaia LA; Cherkashova EA; Samsonova NG; Nilova TV; Sil'verstova SIu Eksp Klin Gastroenterol; 2011; (2):37-43. PubMed ID: 21563361 [TBL] [Abstract][Full Text] [Related]
6. [Therapeutic aspects of metabolic effects of xylitol in diabetics]. Hammerl H; Kränzl C; Nebosis G; Pichler O; Studlar M Wien Z Inn Med; 1971; 52(1):70-4. PubMed ID: 5540821 [No Abstract] [Full Text] [Related]
7. Current world literature. Curr Opin Lipidol; 2011 Dec; 22(6):497-500. PubMed ID: 22101559 [No Abstract] [Full Text] [Related]
8. Treatment implication from the potential association between nonalcoholic fatty liver disease and cardiovascular disease. Shen L Hepatology; 2011 Jul; 54(1):377-8. PubMed ID: 21710476 [No Abstract] [Full Text] [Related]
12. [Influence of lipolysis and its inhibition on the diabetic metabolic disorders and cholesterol levels]. Beringer A; Bänder A; Glaninger J; Mayerhofer E Wien Z Inn Med; 1971; 52(1):1-14. PubMed ID: 5540814 [No Abstract] [Full Text] [Related]
17. [Some parameters of carbohydrate and lipid metabolism in patients with non-alcoholic steatohepatitis]. Mansurov KhKh; Mansurova FKh; Avezov SA; Khuzhamuratov MKh; Mirzoeva PF; Odinaev RI Klin Med (Mosk); 2005; 83(6):47-50. PubMed ID: 16075645 [TBL] [Abstract][Full Text] [Related]
18. Concentration and fatty acid composition of serum lipids in myotonia dystrophica. With special reference to pathogenesis. Wakamatsu H; Nakamura H; Ito K; Anazawa W; Okajima S; Shigeno K; Goto Y Horm Metab Res; 1972 Nov; 4(6):458-62. PubMed ID: 4655500 [No Abstract] [Full Text] [Related]
19. Evaluation of a pharmacist-managed lipid clinic that uses point-of-care lipid testing. Gerrald KR; Dixon DL; Barnette DJ; Williams VG J Clin Lipidol; 2010; 4(2):120-5. PubMed ID: 21122639 [TBL] [Abstract][Full Text] [Related]
20. [Effect of Xue Zhi Kang on the formation of fatty liver in cholesterol-fed rabbits]. Zhang M; Tong Y; Zheng X; Chen Y Zhonghua Gan Zang Bing Za Zhi; 2001 Jul; 9 Suppl():34-6. PubMed ID: 11509134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]